The Indian government has officially implemented a new regulation requiring a valid doctor’s prescription for the purchase of all cough and oral liquid medicines. This policy shift follows a series of tragic incidents involving contaminated syrups, which led to numerous child fatalities both domestically and internationally. By moving away from over-the-counter access, authorities aim to prevent the widespread practice of self-medication and ensure that potent liquid formulations are only used under clinical supervision. This move also aligns with recent recommendations from the National Formulary of India, which has cautioned against providing cough treatments to young children without strict medical necessity.

The decision arrives amidst heightened global scrutiny regarding the safety standards of India’s pharmaceutical sector. Following alarming reports of toxic substances like diethylene glycol—an industrial solvent—found in various exported syrups, the Drugs Controller General of India has taken aggressive steps to audit manufacturing facilities. With over 90 percent of manufacturers already inspected and non-compliant companies facing strict penalties, the government is committed to sanitizing the industry. The ultimate goal is to modernize the nation’s drug regulatory framework to meet international quality benchmarks, ensuring that such life-threatening quality lapses do not recur.